Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT03345563
Official study title

Project HERO: Health Empowerment & Recovery Outcomes

Study summary

Project HERO is a 12-week study of the efficacy of Body Mind Training (BMT, i.e. Tai Chi and Qigong in this project) for reducing fatigue in male cancer survivors. This 3-arm randomized clinical trial will examine inflammatory biology and selected gene-expression pathways that are hypothesized to contribute to the intervention's effect.

Ask AI to explain this study
Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedBody Mind Training (BMT) and Body Training (BT):

Plus 1 other study approaches.

Who it may be forProstate Cancer · Bladder Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 7, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Rutgers, The State University of New Jersey

Study sponsor

01
Study overview

What this study is about

Purpose
Supportive Care
Study type
Interventional
Phase
Not applicable
Sponsor
Rutgers, The State University of New Jersey
Interventions being studied
Behavioral: Body Mind Training (BMT); Behavioral: Body Training (BT):; Behavioral: Usual Care (UC)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Supportive or behavioral care→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Age ≥ 55 years
  • Previous diagnosis of local, regional, or metastatic cancer. If treated for cancer, prostate cancer therapy completed, 3+ months. If on ADT/ hormone manipulation, must be for 4 or more months
  • Previous diagnosis of small intestine, thyroid, oral, non-muscle invasive bladder, kidney/renal, lung, colon, rectum, soft tissue, or other cancer
  • Meet study criteria for fatigue: Medical Health Outcome Study Short Form Vitality/Fatigue subscale (SF-36 Vitality scale-4 items; 5 Likert scale) using a fatigue cut-off value of ≤13; or the Patient-Reported Outcomes Measurement Information System Fatigue scale (PROMIS Fatigue scale) using a cut-off value of ≥9
  • Live within 75 miles of New Brunswick or Newark
  • Inactive (\<150 minutes of vigorous exercise/week within the past 3 months)
  • Has transportation to attend on-site classes and assessments
Reasons someone may not be able to joinExclusion criteria
  • Patient Health Questionnaire PHQ-9 Score \>12
  • Indication of suicidality from PHQ-9 reports that he has several or more days of "thoughts that you would be better off dead, or of hurting yourself."
  • Karnofsky performance status score of 50 or below
  • Current regular practice within the past year (2-3 times a week over a period of two months that is not interrupted) of BMT or other complementary and alternative medicine that shares similar principles of BMT.
  • Inability to speak and read English proficiently
  • Unable to understand informed consent
  • Current health conditions that may interfere with the intervention: respiratory, cardiovascular, or neurological problems unless released by a physician
  • Medical conditions or activities that can cause severe fatigue: Severe hearing loss that would cause difficulty following an instructor in a group setting, chronic fatigue syndrome, current major depression, alcohol use disorder, shift work
  • Prostate cancer that has metastasized to the liver, brain, or lungs
  • Currently receiving chemotherapy with VePesid, Cytoxan, Enzalutamide (XTANDI®), intravenous chemotherapy or radionucleotides (Strontium-89, Samarium (Quadramet®), Radium-223 (Xofigo®)), or other therapy (as confirmed by study team)
  • Unwilling to be randomized to study arms and/or commit to 12 weeks of classes and assessments
  • Have had a diagnosis of another cancer, unless:
  • Non-melanoma skin cancer or
  • Completed treatment AND cancer-free for 5 or more years. We will not include any of the following special populations:
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Rutgers UniversityNew Brunswick, New Jersey

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 7, 2026. Always confirm current availability with the study team.

View original record ↗